Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Juan J Gorgojo Martínez"'
Autor:
José M. González-Clemente, María García-Castillo, Juan J. Gorgojo-Martínez, Alberto Jiménez, Ignacio Llorente, Eduardo Matute, Cristina Tejera, Aitziber Izarra, Albert Lecube
Publikováno v:
Journal of Endocrinology and Diabetes. 9:1-11
Dapagliflozin is a selective sodium-glucose cotransporter 2 nhibitor (SGLT2i) indicated for the treatment of type 2 diabetes mellitus (T2DM), heart failure with reduced ejection fraction and chronic kidney disease. In all indications, treatment can b
Autor:
Juan J. Gorgojo-Martínez, Pedro Mezquita-Raya, Juana Carretero-Gómez, Almudena Castro, Ana Cebrián-Cuenca, Alejandra de Torres-Sánchez, María Dolores García-de-Lucas, Julio Núñez, Juan Carlos Obaya, María José Soler, José Luis Górriz, Miguel Ángel Rubio-Herrera
Publikováno v:
Scientia
Gastrointestinal adverse events; Obesity; Type 2 diabetes Esdeveniments adversos gastrointestinals; Obesitat; Diabetis tipus 2 Eventos adversos gastrointestinales; Obesidad; Diabetes tipo 2 Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29cb7e6eff2e733dc8b6bd9c6b43b525
https://hdl.handle.net/11351/9056
https://hdl.handle.net/11351/9056
Autor:
Jesús Reviriego, Esther Artime, A Sicras-Mainar, Natalia Duque, Silvia Díaz, Xavier Mundet, Jeremie Lebrec, Irene Romera, Juan J. Gorgojo-Martínez, Miriam Rubio, Enrique Carretero-Anibarro
Publikováno v:
Advances in Therapy
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Introduction In the EDITION clinical trial programme, patients with type 2 diabetes mellitus (T2DM) receiving insulin glargine (IGlar) U300 required 10–15% more insulin than those receiving IGlar U100. This study sought to determine whether this di
Autor:
Ketan Kavia, Tina Vilsbøll, Amar Ali, Ben D Prohaska, Juan J Gorgojo Martínez, Irene Hramiak, Akshay Jain, Sten Madsbad, Jodi L Strong, Louis Potier
Publikováno v:
International Journal of Clinical Practice
Jain, A B, Ali, A, Gorgojo Martínez, J J, Hramiak, I, Kavia, K, Madsbad, S, Potier, L, Prohaska, B D, Strong, J L & Vilsbøll, T 2021, ' Switching between GLP-1 receptor agonists in clinical practice : Expert consensus and practical guidance ', International Journal of Clinical Practice, vol. 75, no. 2, e13731 . https://doi.org/10.1111/ijcp.13731
Jain, A B, Ali, A, Gorgojo Martínez, J J, Hramiak, I, Kavia, K, Madsbad, S, Potier, L, Prohaska, B D, Strong, J L & Vilsbøll, T 2021, ' Switching between GLP-1 receptor agonists in clinical practice : Expert consensus and practical guidance ', International Journal of Clinical Practice, vol. 75, no. 2, e13731 . https://doi.org/10.1111/ijcp.13731
Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are an established treatment for patients with type 2 diabetes (T2D). Differences between GLP‐1RAs in pharmacokinetics, dosing regimens and clinical effects, including cardiovasc
Publikováno v:
Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery. 12(10)
Background Current guidelines do not offer detailed recommendations on antidiabetic drug therapy in type 2 diabetes (T2D) after bariatric surgery (BS), and reported experience is scarce. Objectives To evaluate the effectiveness and tolerability of li